+ Watch DCTH
on My Watchlist
The Company is a development stage Company.
As long as Delcath is pinning their hopes on revenues from the Chemosat system, they're likely to be a dead stock walking. The recent reverse split may position them to raise more cash from dilution, but only a masochist would want to own the stock waiting for that to happen. Any bank or fund looking at the ugly picture Delcath has presented over the last three years is going to want a steep discount on the offering and is probably going to short the stock into it in order to juice their returns. Delcath calims that adoption of Chemosat is progressing in the UK and Germany, but they reported no revenue from Europe in the last quarter. A new clinical trial of Chemosat/Melblez in hepatocellular carcinoma probably won't begin enrolling patients until the second half of the year and Delcath is expecting to burn 5-6M/quarter this year. It's hard to see the company ever digging themselves out of this hole.
dropping faser than a rock
This is an observation call, not a recommendation to "play" on CAPS.Studying reverse splits, 1:16 yesterday resulted in a 20% additional selloff. Watched this a few other times and a rebound occurred. Working on theory about how people react to large reverse splits...usually run-up in advance, then drop after then up again....Patterns are patterns until they are not....NO FURTHER analysis on underlay. (not popular with zz, etc.).Close = 7 Days if Green......
Will pass FDA..
This stock will continue to grow will the anticipation of FDA approval.
PDUFA-date of June 14th. Run-up expected in May-2013. Expect run-up to $3.5+
upside potential unlimited when product benefits so many people and company is beaten down by the large drug companies. Delcath will be bought out by bms or pfizer in the near future
Cannot remember who I was following on this pick.
The PHP system they are developing will pass FDA approval and become the standard of care for organ chemotherapy treatment.
DCTH has a lot of cash for a development stage company. And unlike the run up in december to almost $12 per the NDA , this year they have exposure in Europe... could we then see a run up to $15-$16 before the next NDA in Sept 2011?? Something to think about...
Because the FDA did not squash the product but has unresolved questions about it that require clarification.
DCTH is awaiting NDA from the FDA. It has begun to run as a result and its chart looks extremely positive technically. They just disclosed a 5.08% Blackrock stake in FDA 13g filing. And if the CEO is correct with his believe of 15b market potential, this stock is worth many times its current value.
FDA approval very optimistic.
Delcath should get approval for melanoma mid-2011. The opportunity is much bigger for its PHP system though.
This is really a no brainer when you get past all of the rhetoric. They built a system that puts Chemo only into the organ/region with cancer instead of poisoning the whole patient.Once approved by the FDA in 2011 I predict a $50 share price.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions